An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease.

Aims: Selisistat, a selective SirT1 inhibitor is being developed as a potentially disease-modifying therapeutic for Huntington's disease (HD). This was the first study of selisistat in HD patients and was primarily aimed at development of pharmacodynamic biomarkers.

Methods: This was a randomized, double-blind, placebo-controlled, multicentre exploratory study.

Reference genes selection for transcriptional profiling in blood of HD patients and R6/2 mice.

Background: Huntington's disease is a neurodegenerative disorder characterized by transcriptional alterations both in central and peripheral tissues. Therefore, the identification of a transcriptional signature in an accessible tissue can meaningfully complement current efforts in clinical biomarker development. Gene expression normalization represents an essential step in transcriptional signatures identification, and since many reference genes show altered expressions in several pathologies, the definition of stable genes in the desired tissue is required to allow correct result interpretations.

Zerovalent titanium-sulfur complexes. Novel dithiocarbamato derivatives of Ti(CO)6: [Ti(CO)4(S2CNR2)]-.

Oxidation of [Ti(CO)(6)](2-) by thiuram disulfides, (R(2)NCS(2))(2), affords the first isolable mononuclear six-coordinate titanium(0) carbonyls, [Ti(CO)(4)(S(2)CNR(2))](-), which have unusual trigonal prismatic geometries and chemical and spectral properties that are remarkably similar to those of the 18-electron and seven-coordinate anion [Ti(CO)(4)(eta(5)-C(5)H(5))](-).